Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
J Immunol. 2013 Apr 15;190(8):3839-47. doi: 10.4049/jimmunol.1203200.
With the awareness that immune-inflammatory cross-talk is at the heart of many disorders, the desire for novel immunomodulatory strategies in the therapy of such diseases has grown dramatically. As a prime initiator and important modulator of immunological and inflammatory processes, the complement system has emerged as an attractive target for early and upstream intervention in inflammatory diseases and has moved into the spotlight of drug discovery. Although prevalent conditions such as age-related macular degeneration have attracted the most attention, the diverse array of complement-mediated pathologies, with distinct underlying mechanisms, demands a multifaceted arsenal of therapeutic strategies. Fortunately, efforts in recent years have not only introduced the first complement inhibitors to the clinic but also filled the pipelines with promising candidates. With a focus on immunomodulatory strategies, in this review we discuss complement-directed therapeutic concepts and highlight promising candidate molecules.
由于认识到免疫炎症的相互作用是许多疾病的核心,因此人们对这些疾病治疗中新型免疫调节策略的需求急剧增加。补体系统作为免疫和炎症过程的主要启动者和重要调节剂,已成为炎症性疾病早期和上游干预的一个有吸引力的靶点,并成为药物发现的焦点。尽管像年龄相关性黄斑变性这样的常见疾病引起了最多的关注,但由于不同的补体介导的病理具有不同的潜在机制,因此需要多种治疗策略。幸运的是,近年来的努力不仅将第一种补体抑制剂引入临床,而且还为有前途的候选药物填充了研发管线。本文重点讨论了免疫调节策略,讨论了补体靶向治疗的概念,并强调了有前途的候选分子。